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Abstract 
Background: Little is known about factors that affect the composition of contracted blood clots in specific diseases. 
We investigated the content of polyhedral erythrocytes (polyhedrocytes) formed in blood clots and its determinants 
in type 2 diabetes (T2D) patients.
Methods: In 97 patients with long‑standing T2D [median  HbA1c, 6.4% (interquartile range 5.9–7.8)], we measured 
in vitro the composition of blood clots, including a clot area covered by polyhedrocytes using scanning electron 
microscopy and the erythrocyte compression index (ECI), defined as a ratio of the mean polyhedrocyte area to the 
mean native erythrocyte area. Moreover, plasma fibrin clot permeability  (Ks), clot lysis time (CLT), thrombin generation, 
oxidative stress [total protein carbonyl (total PC), total antioxidant capacity and thiobarbituric acid reactive substances 
(TBARS)], and platelet activation markers were determined. The impact of glucose concentration on polyhedrocytes 
formation was assessed in vitro.
Results: Polyhedrocytes content in contracted clots was positively correlated with glucose (r = 0.24, p = 0.028), 
glycated hemoglobin (r = 0.40, p = 0.024), total cholesterol (r = 0.22, p = 0.044), TBARS (r = 0.60, p = 0.0027), P‑selectin 
(r = 0.54, p = 0.0078) and platelet factor‑4, PF4 (r = 0.59, p = 0.0032), but not with thrombin generation, platelet 
count,  Ks or CLT. Patients who formed more polyhedrocytes (≥ 10th percentile) (n = 83, 85.6%) had higher glucose 
(+ 15.7%, p = 0.018), fibrinogen (+ 16.6%, p = 0.004), lower red blood cell distribution width (RDW, − 8.8%, p = 0.034), 
reduced plasma clot density (− 21.8%  Ks, p = 0.011) and impaired fibrinolysis (+ 6.5% CLT, p = 0.037) when compared 
to patients with lesser amount of polyhedrocytes (< 10th percentile). ECI and the content of polyhedrocytes were 
strongly associated with total PC (r = 0.79, p = 0.036 and r = 0.67, p = 0.0004, respectively). In vitro an increase of glu‑
cose concentration by 10 mmol/L was associated with 94% higher polyhedrocytes content (p = 0.033) when com‑
pared to the baseline (7.1 mM). After adjustment for age, sex and fibrinogen, multiple regression analysis showed that 
RDW was the only independent predictor of polyhedrocytes content in T2D (OR = 0.61, 95% CI 0.39–0.92).
Conclusions: Poor glycemic control, together with enhanced platelet activation and oxidative stress, increase the 
content of polyhedrocytes in blood clots generated in T2D patients.
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Introduction
Type 2 diabetes (T2D) is associated with a hypercoagu-
lable state involving increased platelet activation, throm-
bin generation and unfavorable fibrin clot properties 
[1–4]. T2D patients are at high risk of arterial thrombo-
embolism [1, 2, 5] and associated mortality [6–9]. T2D 
patients present significant changes in the morphology of 
their erythrocytes and in the nature of the fibrin formed 
upon the addition of thrombin [10]. Platelet count is usu-
ally within the reference range, however platelet activity 
is increased [11] as reflected among others by elevated 
platelet factor 4 or P-selectin in T2D patients [12–14]. 
Moreover, platelet contractile force has been shown to 
be increased in T2D patients [15]. During clot formation 
platelets activated by thrombin form a platelet–fibrin 
mesh constituting the basic structure of thrombus in vivo 
or whole blood clot in  vitro [16]. Such clots undergo 
volume shrinkage [17] that is called clot contraction or 
retraction [18]. Cellular blood components, in particular 
red blood cells (RBCs), platelets, and plasma fibrinogen 
concentration influence the rate and extent of clot con-
traction [18]. It has been postulated that RBCs enhance 
functional coagulation properties and platelet aggrega-
tion. RBC aggregation and decreased deformability are 
the dominant hematological abnormalities in T2D sub-
jects and may lead to the development of microvascular 
complications [19]. Reduced clot contraction has been 
demonstrated in subjects with a lower platelet count 
and/or dysfunction, elevated hematocrit, leukocyto-
sis, increased plasma fibrinogen, and other changes in 
blood composition that may affect platelet function and 
properties of blood clots [20] [21]. It has been suggested 
that defective clot retraction contributes to arterial 
and venous thrombosis [22]. Cines et  al. have demon-
strated that contracted blood clots and arterial thrombi 
developed a tessellated structure of polyhedral erythro-
cytes, called polyhedrocytes [18]. Polyhedrocytes were 
observed in the interior of the blood clot, where the 
RBCs were tightly compressed, with meshwork of fibrin 
and platelets on its surface [18, 23]. It has been postu-
lated that polyhedrocytes provide impermeable seal, 
due to minimal interstitial space, which stems bleeding 
and promotes fibrinolysis resistance [18, 23]. We have 
reported that polyhedrocytes are observed in 20% of 
thrombi obtained from epicardial arteries of ST-elevation 
myocardial infarction patients [18, 23, 24]. Formation of 
polyhedrocytes in arterial thrombi has been associated 
with higher RBC count and both lower platelet count and 
plasma fibrinogen, but not with cardiovascular risk fac-
tors or the ischemia time [25].
To our knowledge, there have been no reports on deter-
minants of polyhedrocyte formation in clots of patients 
with T2D. RBCs are extremely sensitive to oxidative 
stress or cytokine upregulation. This usually accompanies 
systemic inflammation in most diseases, including T2D 
[26]. We hypothesized that poor metabolic control, along 
with prothrombotic plasma clot phenotype, enhanced 
platelet activation and oxidative stress observed in T2D 
patients with high cardiovascular risk, are associated 
with higher content of polyhedrocytes.
Research design and methods
We enrolled 97 consecutive T2D patients with high car-
diovascular risk hospitalized from August 2015 to April 
2016 in John Paul II Hospital in Krakow, Poland and 30 
apparently healthy controls. All patients fulfilled the 
American Diabetes Association criteria for diagnosis of 
T2D and were treated for at least 12 months. The exclu-
sion criteria were arterial or venous thromboembolic 
events within previous 6  months, current anticoagulant 
therapy, known cancer, signs of acute infection, chronic 
inflammatory disorders (e.g. rheumatoid arthritis), liver 
injury (alanine or asparagine transaminase > 1.5 times 
above the upper limit of the reference range), estimated 
glomerular filtration rate (eGFR) < 30 mL/min, and preg-
nancy. Current smoking was defined as smoking at least 
one cigarette daily. Arterial hypertension was defined as 
a systolic and/or diastolic blood pressure of ≥ 140 mmHg 
or ≥ 90 mmHg, respectively or a history of arterial hyper-
tension with or without taking antihypertensive agents. 
Coronary artery disease (CAD) was established based on 
a documented history of myocardial infarction (MI) or 
a positive result of ECG stress test or gated single pho-
ton emission computed tomography with Tc-99 m-MIBI 
(SPECT) or a coronary angiography. Previous MI was 
established based on medical records.
The Jagiellonian University Ethical Committee 
approved the study and all the participants provided their 
written informed consent.
Routine laboratory investigations
Fasting venous blood was drawn between 7 and 10 A.M. 
and was kept at a room temperature. Blood samples were 
collected into citrated tubes (9:1 of 0.106 M sodium cit-
rate), centrifuged at 2500g and 20 °C for 10 min to obtain 
platelet poor plasma (PPP), snap-frozen within 60 min, 
and stored in small aliquots at − 80  °C until analysis. 
The activated partial thromboplastin time (aPTT), cre-
atinine, eGFR, serum total cholesterol (TC), low-density 
lipoprotein cholesterol (LDL-C), high-density lipopro-
tein cholesterol (HDL-C), triglycerides (TG), glucose 
and thyroid stimulating hormone (TSH) were assayed 
by routine laboratory techniques. Glycated hemoglobin 
A1c  (HbA1c) was measured using immunoturbidimetry 
(Roche Diagnostics GmbH, Mannheim, Germany). Com-
plete blood count including white blood cells (WBC), 
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RBC, hemoglobin, hematocrit, red blood cell distribution 
width (RDW), platelet count and platelet distribution 
width were assayed. Fibrinogen was assessed using the 
Clauss method. The hsCRP was determined using immu-
noturbidimetry (Roche Diagnostics GmbH, Mannheim, 
Germany). Immunoenzymatic assay was used to deter-
mine plasminogen activator inhibitor-1 (PAI-1) antigen 
(American Diagnostica, Stamford, CT, USA) in citrated 
plasma. Plasma α2-antiplasmin (α2AP) and plasminogen 
were measured by chromogenic assays (STA Stachrom 
antiplasmin and STA Stachrom plasminogen, Diagnos-
tica Stago, Asnieres, France). Markers of platelet activa-
tion, P-selectin (CD62P) and platelet factor-4 (PF4), were 
determined in citrated plasma by ELISAs (R&D Systems, 
Abington, UK). The interassay and intraassay coefficients 
of variation for all the ELISAs were < 8%.
Preparation of whole blood clots
Clotting was initiated by addition of 2  µL of activation 
mixture  (CaCl2 [Sigma-Aldrich, St. Louis, MO, US] and 
human thrombin [Merck KGaA, Darmstadt, Germany] at 
final concentrations of 0.01 M and 1 U/mL, respectively) 
to 48  μL of whole blood from the antecubital vein that 
was prewarmed for 5  min at 37  °C. The samples were 
incubated at room temperature for 24 h.
Scanning electron microscopy
Scanning electron microscope (SEM) analysis was per-
formed as previously described [27]. Blood clots were 
washed in 0.1  M NaCl for several minutes and fixed in 
2.5% glutaraldehyde, dehydrated in raised ethanol con-
centrations and frozen in tert-Butyl alcohol for 2  h. 
Then, clots were dried in a vacuum and coated with gold. 
High-definition photographs were acquired using a scan-
ning electron microscope (JEOL JCM-6000, Japan). We 
performed analysis of polyhedrocytes content and size 
measurement in 40 selected areas located in 3 vertical 
axes (from the left to the right and from the top to the 
bottom of the clot) with a subjective evaluation of the 
area covered by RBC, polyhedrocytes, or their transi-
tional forms (Fig. 1).
For the semiquantitative analysis, each picture was 
divided into 400 squares and the dominant composition 
(platelets, fibrin, erythrocytes, WBC) of each was assayed 
(Fig. 1). The visual approach consisted of a careful obser-
vation of each pictures with a subjective evaluation of 
the percentage of each component. Two independent 
investigators performed visual approach. Very low inter-
individual variability was found in the clot composition 
analysis (< 7%). The investigators performing SEM and 
analysis were blinded to the clinical data. Images for each 
clot were then assessed using ImageJ (US National Insti-
tutes of Health) to determine the area (µm2) of native 
RBCs and polyhedrocytes. Results were presented as 
means ± standard deviations (SD) of about 100 consecu-
tive RBC areas obtained from each SEM image.
Erythrocyte compression index
Erythrocyte compression index (ECI) was determined as 
previously described [28]. Briefly, ECI is defined as a ratio 
of the mean polyhedrocyte area to the mean native RBC 
area expressed as a percentage. Two investigators evalu-
ated the first 10 clots with the inter-observer and intra-
observer agreement of 93% and 95%, respectively.
Thrombin generation potential
Plasma thrombogenic potential was assessed using cali-
brated automated thrombography (CAT) (Thrombino-
scope BV, Maastricht, the Netherlands) in a 96-well plate 
fluorometer (Ascent Reader, Thermolab systems OY, Hel-
sinki, Finland) at 37  °C according to the manufacturer’s 
instructions. Eighty microliters of platelet poor plasma 
were diluted with 20 µL of a commercially available tissue 
factor (TF)-based activator (Diagnostica Stago, Asniéres, 
France) containing 5  pM recombinant TF, 4 micromo-
lar phosphatidylserine/phosphatidylcholine/phosphati-
dylethanolamine vesicles, and 20  µL of FluCa solution 
(Hepes, pH 7.35, 100  nmol/L  CaCl2, 60  mg/mL bovine 
albumin, and 2.5  mmol/L Z-Gly-Gly-Arg-amidometyl-
coumarin). The reference ranges of thrombin genera-
tion potential were as follows: Lag time, 1.57 ± 0.33 min; 
ETP, 1694 ± 373  nM × min; Peak thrombin generation, 
360 ± 108 nM; ttPeak, 3.96 ± 0.71 min [29].
Fibrin clot permeability and lysis
Fibrin clot permeability was determined using a pres-
sure-driven system [30]. Briefly, 20 mM calcium chloride 
and 1 U/mL human thrombin (Merck KGaA) were added 
to 120 µL citrated plasma. A permeation coefficient  (Ks), 
which indicates the pore size, was calculated from the 
equation:
where Q is the flow rate in time t; L, the length of a fibrin 
gel; η, the viscosity of liquid (in poise); A, the cross-sec-
tional area (in  cm2), and Δp, a differential pressure (in 
dyne/cm2).
To assess efficiency of clot lysis, citrated plasma was 
mixed with 15  mM calcium chloride, 6  pM human tis-
sue factor (Innovin, Siemens), 12 μM phospholipid vesi-
cles and 60  ng/mL recombinant tPA (rtPA, Boehringer 
Ingelheim, Germany). The mixture was transferred to 
a microtiter plate and its turbidity was measured at 
405  nm at 37  °C. Clot lysis time (CLT) was defined as 
the time from the midpoint of the clear-to-maximum-
turbid transition, which represents clot formation, to 
Ks = Q× L× η/t× A×�p,
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the midpoint of the maximum-turbid-to-clear transition 
(representing the lysis of the clot). The reference ranges 
of fibrin clot permeability and lysis were as follows: Ks, 
7.01 ± 2.06 × 10−9cm2; CLT, 100 ± 9.7 min [29, 31].
Total protein carbonyl (total PC) assessment
Oxidative modification of plasma proteins was assessed 
based on carbonyl content using 2–4 dinitrophenylhy-
drazine (DNPH), as reported by Becatti et al. [32]. DNPH 
reacts with PC, forming a Schiff base to produce the 
corresponding hydrazone, which can be analyzed spec-
trophotometrically. Briefly, citrated PPP (100  µL) after 
incubation with DNPH (400  µL) was precipitated with 
trichloracetic acid (TCA) and the pellet washed sev-
eral times with a 1:1 mixture of ethanol/ethyl acetate. 
Finally, the pellet was resuspended in 500  µL guanidine 
hydrochloride and measured at 370  nm. PC content 
was calculated by using a molar extinction coefficient of 
22,000  M−1  cm−1. The results, expressed as nM/mL of 
PC, were then normalized for protein concentration. The 
reference range of total PC was 1.82 ± 0.2 nmol/mg [33].
TBARS (thiobarbituric acid reactive substances) estimation
Thiobarbituric acid reactive substances levels were meas-
ured in citrated PPP using a TBARS assay kit (OXI-TEK, 
ENZO, USA) in accordance with the manufacturer’s 
instructions as previously reported [32]. Briefly, the 
adduct generated by reacting malondialdehyde with thio-
barbituric acid after 1 h at 95 °C was measured spectro-
fluorimetrically, with excitation at 530 nm and emission 
at 550 nm. TBARS were expressed in terms of malondi-
aldehyde equivalent (nM/mL) and then normalized for 
protein concentration. The reference range of TBARS 
was: 18.6 ± 1.16 nmol/mL [33].
Fig. 1 A representative SEM images of a retracted whole blood clot (magnifications ×30 and ×3600) used for semiquantitative analysis of 
polyhedrocytes content and size measurement in 40 selected areas located in 3 vertical axes (from the left to the right and from the top to the 
bottom of the clot). a and b clot surface area containing fibrin cup and native red blood cells (RBCs) and eryptotic cells (marked with arrows), c and 
d transitional clot area composed mostly of transitional forms of polyhedrocytes and fibrin fibers, e and f clot internal area mainly composed of 
polyhedrocytes and small amounts of fibrin located on the edges of polyhedral RBCs
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Total antioxidant capacity (TAC) assay
The ORAC method (oxygen radical absorbance capac-
ity), based on the inhibition of the peroxyl-radical-
induced oxidation initiated by thermal decomposition 
of azo-compounds, like 2,2icazobis(2-amidinopropane) 
dihydrochloride (AAPH), was performed as reported by 
Becatti et  al. [32]. Briefly, a fluorescein solution (6  nM) 
prepared daily from a 4  µM stock in 75  mM sodium 
phosphate buffer (pH 7.4), was used. Trolox (250 μM final 
concentration) was used as a standard. 70 μL of citrated 
PPP with 100  μL of fluorescein were pre-incubated for 
30 min at 37 °C in each well, before rapidly adding AAPH 
solution (19  mM final concentration). Fluorescence was 
measured with excitation at 485  nm and emission at 
537 nm in a Fluoroskan Ascent Microplate Fluorometer 
(Thermo Fisher Scientific Inc. MA, USA). Results were 
expressed as Trolox Equivalents (μM) and then normal-
ized for protein concentration. The reference range of 
TAC assay was: 378.86 ± 20.82 nmol/mL [33].
The oxidation parameters, platelet markers, and 
fibrinolytic proteins were measured in a subset of 
patients (n = 23).
An influence of exogenous glucose on polyhedrocyte 
formation
To assess the direct influence of glucose concentration 
on polyhedrocytes formation, we added 10  mM glu-
cose solution in 0.9% sodium chloride to blood obtained 
from randomly selected 10 healthy (5 men and 5 women 
aged 39–60 [median, 47] years; mean glucose level of 
4.9 [IQR: 4.6–5.2] mM) and 7 randomly selected T2D 
subjects (3 men and 4 women aged 31–76 [median, 74] 
years; mean glucose level of 7.1 [IQR: 6.6–7.9] mM). The 
samples were incubated at 37 °C for 1 h. Then, the whole 
blood clots were prepared in duplicate and analyzed 
as described above by two independent investigators 
blinded to the clinical data.
Statistical analysis
Continuous variables were presented as mean and stand-
ard deviation or median with the first and the third 
quartile depending on data distribution assessed using 
Shapiro–Wilk test and compared using Student’s t test or 
Wilcoxon test. Nominal variables were described using 
counts and percentages and compared using χ2 test of 
Fisher’s Exact Test. Pearson’s or/and Spearman’s cor-
relations were calculated when applicable for measur-
ing the association between two continuous variables. 
The change in analyzed variables due to the increase in 
polyhedrocytes by 1% was assessed using linear regres-
sion. Several logistic regression models with production 
of polyhedrocytes as a dependent variable (production 
occurred or not occurred). The best model was then 
obtained stepwise backwards minimalizing Bayesian 
Information Criterion (BIC) with variables gender, age 
and level of fibrinogen locked in the model for adjust-
ment. Association between the variables was expressed 
as odds ratio (OR) with corresponding 95% confidence 
intervals (CI). A p-value < 0.05 was considered statisti-
cally significant.
Results
Patient characteristics
The final analysis included 97 patients with a well-con-
trolled (median  HbA1c, 6.4%), long-standing (median 
duration, 9.3  years) T2D (Table  1) and 30 age-matched 
healthy controls (64.39 ± 10.12  years) not taking any 
medications. A majority of patients were at high risk of 
CAD and were treated as recommended in the current 
guidelines, including aspirin (Table 1).
Polyhedrocytes formation
We divided the study group based on the percentage of 
the polyhedrocytes content on the surface of contracted 
blood clots. Patients in the lowest polyhedrocyte group 
(below 10th percentile of the observations, n = 14) were 
considered as a low-polyhedrocytes group (LP), in con-
trast to the rest of the patients (latter 90% of observations, 
n = 83) who were considered as a high-polyhedrocytes 
group (HP). Median percentage of polyhedrocytes in 
blood clots in the HP group was 20% (interquartile range, 
IQR, 7.7–32.5%) and it was 51% lower than in healthy 
controls (41 [30–61.5]%, p < 0.01). There were no differ-
ences between the HP and LP groups in demographic 
and clinical characteristics including the medications 
used (Table  1). The HP group had higher glucose and 
fibrinogen levels (+ 15.7%, p = 0.018; + 16.6%, p = 0.004 
respectively) and lower RDW (− 8.8%, p = 0.034) with 
no difference in leukocyte or platelet count and lipid 
profiles (Table 2), when compared with the LP subjects. 
Additionally, the HP group showed lower Ks by 21.8% 
(p = 0.011) and increased CLT by 6.5% (p = 0.037) when 
compared with the remainder (Table 3).
In the whole group polyhedrocytes content was posi-
tively correlated with glucose and TC levels (r = 0.24, 
p = 0.028 and r = 0.22, p = 0.044, respectively), but not 
with other lipid parameters. Compared with patients 
with glucose < 6  mmol/L, those with higher glycemia 
were more prone to form greater amounts of polyhedro-
cytes (OR = 4.81, 95% CI 1.49–16.40, p = 0.009).
Platelet markers, fibrinolytic proteins and oxidation 
parameters are presented in Additional file 1: Table S1. 
The content of polyhedrocytes was positively corre-
lated with P-selectin (r = 0.54, p = 0.0078) and PF4 
(r = 0.59, p = 0.0032), but not with platelet count, which 
was within the reference range for all patients. Of the 
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oxidative stress markers, the content of polyhedro-
cytes was strongly associated with total PC (r = 0.67, 
p = 0.0004) and TBARS (r = 0.60, p = 0.0027).
Compression of erythrocytes
In the HP patients the median of the new parameter 
describing compression of erythrocytes, ECI was 59.4 
(53.7–69.6)%. There were no associations between 
ECI and demographic or clinical parameters in those 
patients. ECI was strongly associated with total PC 
(r = 0.79, p = 0.036) and with fibrinogen level (r = 0.29, 
p = 0.030).
Clot composition
The detailed analysis of the blood clot composition 
(n = 40) showed that their major components were native 
erythrocytes (32.6 ± 16.6%), transitional erythrocytes 
(28 ± 12.6%), and fibrin (24.5 ± 9.4%). Polyhedrocytes 
accounted for nearly 8% and platelets for 1% of clot com-
position. Interestingly, the percentage of polyhedrocytes 
was positively associated with  HbA1c (r = 0.40, p = 0.024) 
(Fig. 1).
The influence of exogenous glucose on polyhedrocyte 
formation
The in  vitro increase of glucose concentration from 
4.9 to 14.9  mmol/L in blood obtained from healthy 
subjects was associated with higher content of poly-
hedrocytes (36 [19–44] % to 47 [43–55]%; p = 0.044). 
Similarly in T2D subjects the increase of blood glucose 
concentration from 7.1 to 17.1 mmol/L was associated 
with increased content of polyhedrocytes (from 17 
[14.5–24.2]% to 33 [25–41.9]%; p = 0.033).
Predictors of the HP content
After adjustment for age, sex and fibrinogen, multi-
ple logistic regression analysis showed that increasing 
RDW was the only negative independent predictor of 
polyhedrocytes content in clots (OR = 0.61, 95% CI 
0.39–0.92). Simple linear regression models showed 
that 1% increase in percentage of polyhedrocytes was 
significantly associated with the increase in TBARS (by 
0.4%), total PC (by 0.5%), P-selectin (by 0.5%), and PF4 
(by 0.3%) (Table 4).
Table 1 Patient characteristics
Values are given as number (percentage), mean ± SD or median (interquartile range)
Low polyhedrocytes group represents lowest 10% of the observations. High polyhedrocytes group represents highest 90% of the observations
ACEI angiotensin-converting-enzyme inhibitors, ARB angiotensin receptor blockers, BMI body mass index, MI myocardial infarction, T2D type 2 diabetes
Variable All patients (n = 97) Low polyhedrocytes group 
(n = 14)
High polyhedrocytes group 
(n = 83)
p-value
Male sex, n (%) 63 (64.95) 11 (78.57) 52 (62.65) 0.37
Age, years 67.49 ± 8.82 70.64 ± 10.98 66.96 ± 8.36 0.15
Current smoking, n (%) 22 (22.68) 4 (28.57) 18 (21.69) 0.73
BMI, kg/m2 30.5 (27.4–34.4) 30.4 (28.1–35.7) 30.6 (27.2–34.1) 0.79
Hypertension, n (%) 93 (95.88) 13 (92.86) 80 (96.39) 0.47
Coronary artery disease, n (%) 74 (76.29) 11 (78.57) 63 (75.90) 1.00
T2D time since diagnosis, years 9.30 (5.75–14.30) 7.50 (5.25–15.00) 9.45 (6.00–13.98) 0.94
Drugs
 Sulphonylurea, n (%) 37 (38) 7 (50) 30 (36) 0.38
 Biguanide, n (%) 61 (63) 6 (43) 55 (66) 0.13
 Insulin, n (%) 25 (26) 4 (29) 21 (25) 0.75
 Beta‑blocker, n (%) 82 (85) 12 (86) 70 (84) 1.00
 ACEI, n (%) 67 (69) 12 (86) 55 (66) 0.21
 Calcium antagonist, n (%) 32 (33) 3 (21) 29 (35) 0.38
 Clopidogrel, n (%) 22 (23) 5 (36) 17 (20) 0.30
 Aspirin, n (%) 79 (81) 13 (93) 66 (80) 0.46
 Statin, n (%) 80 (82) 14 (100) 66 (80) 0.12
 ARB, n (%) 17 (18) 2 (14) 15 (18) 1.00
 Loop diuretic, n (%) 30 (31) 6 (43) 24 (29) 0.35
 Spironolactone, n (%) 22 (23) 3 (21) 19 (23) 1.00
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Discussion
The present study identifies several factors that affect 
formation of polyhedrocytes in patients with T2D 
and high cardiovascular risk. Our study is the first to 
demonstrate that both the glycaemia and  HbA1c were 
associated with increased polyhedrocytes formation in 
T2D patients, which was confirmed by in vitro experi-
ment. Moreover, increased platelet activation, reflected 
by plasma concentrations of P-selectin and PF4, and 
protein oxidation, in particular total PC, were the 
major determinants of polyhedrocytes formation in 
blood clots of T2D patients. Our findings indicate that 
Table 2 Laboratory investigations
Values are given as mean ± SD or median (interquartile range)
Low polyhedrocytes group represents lowest 10% of the observations. High polyhedrocytes group represents highest 90% of the observations
aPTT activated partial thromboplastin time, eGFR estimated glomerular filtration rate based on a Modification of Diet in Renal Disease (MDRD) formula, HDL-C high-
density lipoprotein cholesterol; HGB, hemoglobin, HCT hematocrit, hsCRP high sensitivity C-reactive protein, INR international normalized ratio, LDL-C low-density 
lipoprotein cholesterol, PDW platelet distribution width, RBC red blood cells, RDW red blood cell distribution width, PLT platelet count, TC total cholesterol, TG 
triglycerides, TSH thyroid-stimulating hormone, WBC white blood cells, ACEI angiotensin-converting-enzyme inhibitors, ARB angiotensin receptor blockers, BMI body 
mass index, MI myocardial infarction, T2D type 2 diabetes
Variable All subjects (n = 97) Low polyhedrocytes group 
(n = 14)
High polyhedrocytes group 
(n = 83)
p-value
Fibrinogen, g/L 3.31 ± 0.58 2.90 ± 0.46 3.38 ± 0.57 0.004
INR 1.00 (0.96–1.03) 1.02 (0.98–1.06) 0.99 (0.95–1.03) 0.22
aPTT, sec 25.00 (23.95–26.20) 24.75 (24.30–25.10) 25.10 (23.60–26.30) 0.80
WBC, 103/µL 6.93 ± 1.61 7.51 ± 1.62 6.83 ± 1.59 0.15
RBC,106/µL 4.64 (4.31–4.94) 4.62 (4.21–5.29) 4.64 (4.31–4.92) 0.82
HGB, g/dL 13.60 (12.90–14.50) 13.15 (11.98–14.33) 13.60 (13.00–14.50) 0.08
HCT, % 40.20 (38.70–42.90) 39.25 (36.30–42.43) 40.30 (38.70–42.90) 0.30
RDW, % 13.50 (13.00–14.50) 14.80 (13.00–15.90) 13.50 (12.90–14.40) 0.034
PLT 103/µL 204.00 (161.50–249.50) 207.50 (157.50–252.50) 204.00 (166.00–250.00) 0.87
PDW, fL 12.60 (11.40–14.50) 13.20 (11.40–14.80) 12.35 (11.38–14.50) 0.56
Glucose, mmol/L 6.60 (5.90–7.75) 5.70 (5.45–6.83) 6.60 (6.10–7.80) 0.018
HbA1c, % 6.40 (5.93–7.10) 6.50 (5.60–7.08) 6.40 (6.00–7.13) 0.78
Creatinine, µmol/L 82.00 (69.50–96.50) 81.00 (72.25–104.75) 82.00 (68.00–96.00) 0.72
eGFR (mL/min/1.73 m2) 76.97 ± 19.10 79.14 ± 22.79 76.60 ± 18.55 0.64
TC, mmol/L 3.93 (3.25–4.74) 3.69 (3.17–4.16) 4.08 (3.26–4.75) 0.30
LDL‑C, mmol/L 2.19 (1.67–3.02) 1.79 (1.61–2.80) 2.26 (1.78–3.04) 0.31
HDL‑C, mmol/L 1.22 (0.95–1.49) 1.24 (0.83–1.41) 1.22 (0.98–1.53) 0.78
TG, mmol/L 1.33 (1.03–1.73) 1.27 (0.98–2.09) 1.37 (1.03–1.73) 0.67
TSH, mIU/L 1.39 (0.84–2.05) 0.98 (0.88–1.88) 1.48 (0.84–2.12) 0.57
hsCRP, mg/L 2.29 (0.95–4.00) 1.35 (0.97–2.43) 3.02 (0.95–4.23) 0.11
Table 3 Coagulation and fibrin clot properties in T2D patients
Values are given as mean ± SD or median (interquartile range)
Low polyhedrocytes group represents lowest 10% of the observations. High polyhedrocytes group represents highest 90% of the observations
ETP endogenous thrombin potential, ttPeak time to thrombin generation peak, Ks, fibrin clot permeability coefficient, CLT clot lysis time
Variable All subjects (n = 97) Low polyhedrocytes group 
(n = 14)
High polyhedrocytes group 
(n = 83)
p-value
Lag time, min 2.90 (2.56–3.67) 2.95 (2.54–3.59) 2.81 (2.57–3.67) 0.93
ETP, nM × min 1367.6 (1289.9–1504.8) 1338.7 (1128.0–1380.5) 1382.5 (1291.6–1511.4) 0.15
Peak thrombin generation, 
nM
264.3 (222.9–309.3) 240.3 (224.4–268.2) 266.0 (222.2–310.9) 0.27
ttPeak, min 5.81 (5.00–7.00) 5.94 (5.48–6.90) 5.67 (5.00–7.05) 0.45
Ks, × 10−9  cm2 5.72 (4.30–6.84) 6.77 (5.56–7.69) 5.56 (4.25–6.57) 0.011
CLT, min 112.0 (100.0–127.0) 108.0 (96.0–114.3) 115.0 (103.0–130.0) 0.037
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regulation of polyhedrocyte formation in clots is com-
plex and dependent on factors other than RBC, platelet 
count and fibrinogen concentration.
Moreover, the link between the extent of oxidative 
stress and polyhedrocytes formation in T2D is also a 
novel observation. We found that compression of the 
erythrocytes measured as a new parameter called ECI 
in patients with T2D was strongly positively associated 
with protein oxidation. Therefore, we may speculate 
that disturbed clot contraction associated with oxidative 
stress in patients with a long-standing history of T2D 
and high cardiovascular risk could be one of the mech-
anisms behind increased atherothrombotic complica-
tion in those patients. Recently ECI was investigated in 
patients with venous thromboembolism (VTE) [28]. In 
contrast to VTE patients in whom ECI was related to age, 
BMI, platelet count and RDW [28] no such relationships 
were observed in our patients with T2D. Similarly to pre-
vious observations in patients with stroke and VTE clot 
contraction in T2D was associated with fibrinogen level 
[28, 34]. It has been shown, that compression of eryth-
rocytes was preferably associated with platelet/fibrinogen 
ratio rather than the platelet or fibrinogen alone [18, 28, 
35]. This may indicate the importance of major plate-
lets effect, which can be modulated by the fibrin, and its 
influence on the clot contraction [18, 23].
RBCs are especially sensitive cells, therefore they are 
important health indicators [26]. Assessment of RBCs 
in terms of biophysical and shape changes such as eryp-
tosis, may be helpful in the evaluation of hematological 
changes associated with inflammatory status or disease 
progression [26, 36–38]. We have observed eryptotic 
cells within clots made from the whole blood obtained 
from T2D patients (Fig. 1a, marked with arrows).
The clot’s ability to contract is a feature of each patient 
and could be modulated by many transient factors [21]. 
The major players in this process are platelets and fibrin 
[34]. During clot contraction, fibrinogen and fibrin fib-
ers are required as the substrate upon which the aggre-
gating platelets pull, and the fibrin(ogen) connecting the 
platelets binds to the platelet integrin αIIbβ3. Clot con-
traction driven by platelet contractile proteins, particu-
larly by the actin-myosin interactions is crucial especially 
in the first phase of clot contraction [23, 39]. Through 
keeping a local tension to reestablish the fibrin-fibrin 
network, the platelet/fibrin ratio was found to play an 
important role in clot contractility [23]. Furthermore, 
clot retraction requires energy which is derived from 
glucose metabolism by platelets and in the absence of 
glucose, retraction will not occur [40]. In our study, we 
demonstrated that platelet-derived proteins, i.e. P-selec-
tin and PF4 released from alpha granules upon activation 
were associated with the increased content of polyhedro-
cytes in blood clots. This is a novel observation. Grow-
ing evidence suggests that oxidative stress can affect 
platelet reactivity and intensify platelet aggregation pro-
cess [41]. Therefore, it seems that the oxidative stress can 
also affect fibrin clot contraction by affecting the plate-
let reactivity. Nevertheless, platelets in T2D patients are 
displaying an ‘angry’ behavior. The lysosomal granules 
might have a significant role in T2D followed by cardio-
vascular complications [42]. Platelet surface receptors 
and platelet activation were found to be elevated in T2D, 
showing increased procoagulant activity and hyperreac-
tivity [42, 43]. These coagulopathies are accompanied by 
augmented LPS-binding protein (LBP) levels [44].
Tutwiler et  al. reported that higher hematocrit along 
with an increased RBC rigidity were associated with lim-
ited clot contractility [23]. In our study, T2D patients who 
formed more polyhedrocytes within blood clots had sim-
ilar RBC and hematocrit, but lower RDW. Moreover after 
the adjustments, lower RDW was the only independent 
predictor of greater polyhedrocytes formation. It is pos-
sible that erythrocytes of similar size are more likely to 
form polyhedrocytes, while different sizes of RBCs hin-
der this process. Thus, increased RDW would result in 
poorer ability of erythrocytes to provide an imperme-
able seal, due to minimal interstitial space, to increase 
fibrinolysis resistance. Furthermore, the inflammatory 
process might play an important role in increased RDW 
Table 4 Regression analysis of  the  influence of  the  increased polyhedrocytes content in  blood clots of  T2D (increase 
by 1%)
R2 represents the coefficient that is a measure of fitting the model
PF4 platelet factor 4, TBARS thiobarbituric acid reactive substances, total PC plasma, total protein carbonyl in plasma
Variable Estimated change 
of the variable
Standard error p-value R2 (%)
TBARS, nmol/mL 0.14 0.037 0.0018 41.0
Total PC plasma, nmol/mg 0.012 0.0028 0.0005 48.2
P‑selectin, ng/mL 0.13 0.059 0.048 19.0
PF4, ng/mL 0.38 0.15 0.019 25.7
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values by releasing the immature RBCs which may con-
tribute to the impaired clot contraction [45]. This issue 
requires further investigation.
We have shown positive association of polyhedrocytes 
formation with worse glycemia control. Moreover, in the 
vitro experiment we demonstrated, that higher glucose 
concentration is associated with higher polyhedrocyte 
content in blood clots. Erythrocytes of patients with T2D 
exhibit impaired deformability related to increased  HbA1c 
and accumulation of intracellular sorbitol or to the stiff-
ness of red blood cell membranes probably due to oxida-
tive modification of the proteins and to an imbalance of 
the cholesterol/phospholipids ratio [46]. Moreover, RBCs 
incubated in an elevated level of glucose showed a signifi-
cantly increased protein glycation and induced ATPases 
activity [47] and were are highly susceptible to oxidative 
damage as a result of the high polyunsaturated fatty acid 
content of their membranes and the high cellular con-
centration of oxygen and hemoglobin [46]. Therefore, we 
hypothesize that these processes may impact the rheo-
logical properties of RBCs, cause membrane damage and 
potentially alter the RBCs contraction, influencing blood 
clot shrinkage properties.
Patients who formed more polyhedrocytes in our study 
showed also prothrombotic fibrin clot properties, such as 
decreased  Ks or prolonged CLT. We have previously dem-
onstrated that prothrombotic fibrin clot phenotype and 
impaired fibrinolysis might be associated with prolonged 
T2D duration [48]. Moreover, we have previously shown 
that in VTE patients, greater ECI (less compression) was 
associated with prolonged CLT, when compared to con-
trols [28]. Carroll et al. have also shown that clot contrac-
tion significantly facilitated clot lysis [22]. The current 
findings suggest that fibrin features measured in plasma 
clots generated in vitro that are related to T2D may also 
be the markers of clot compression.
Limitations
First, a limited number of patients have been included 
in the study, therefore subgroup comparisons should be 
analyzed cautiously. Second,  HbA1c was measured using 
immunoturbidimetry, but not by high-performance liq-
uid chromatography. Third, we did not measure the RBCs 
membranes rigidity or assess function of platelets such 
as platelet aggregation. It is unclear whether polyhedro-
cytes formation affects the risk of cardiovascular events 
or thrombosis in T2D as suggested by other studies with 
regard to MI [24] or stroke [34]. Finally, subjects of the 
present study were all Caucasians, and we did not analyze 
genetic subtypes of the subjects studied.
Conclusions
Increased glucose levels, enhanced oxidative stress and 
platelet activation were associated with increased forma-
tion of polyhedrocytes in contracted blood clots. The sig-
nificance of in vivo polyhedrocytes in T2D and in other 
diseases remains to be established and further studies are 
necessary to demonstrate the role of polyhedrocytes in 
thromboembolic events.
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